The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Animals
Antibodies, Monoclonal, Humanized
/ pharmacology
Carcinogenesis
/ genetics
Cell Line, Tumor
Female
Gene Expression
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Fusion
/ drug effects
Humans
MCF-7 Cells
Mice
Neoplasms
/ genetics
Neuregulin-1
/ genetics
Protein Binding
Receptor, ErbB-2
/ metabolism
Receptor, ErbB-3
/ immunology
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
12
09
2020
revised:
02
01
2021
accepted:
19
03
2021
pubmed:
8
4
2021
medline:
22
3
2022
entrez:
7
4
2021
Statut:
ppublish
Résumé
Oncogenic fusions involving the We developed novel patient-derived and isogenic models of NRG1-rearranged cancers and examined the effect of the anti-HER3 antibody, seribantumab, on growth and activation of signaling networks Seribantumab inhibited NRG1-stimulated growth of MCF-7 cells and growth of patient-derived breast (MDA-MB-175-VII, Seribantumab treatment blocked activation of the four ERBB family members and of downstream signaling, leading to inhibition of
Identifiants
pubmed: 33824166
pii: 1078-0432.CCR-20-3605
doi: 10.1158/1078-0432.CCR-20-3605
pmc: PMC8172458
mid: NIHMS1688761
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
NRG1 protein, human
0
Neuregulin-1
0
seribantumab
1N3L70MDFX
ERBB2 protein, human
EC 2.7.10.1
ERBB3 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Receptor, ErbB-3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3154-3166Subventions
Organisme : NCI NIH HHS
ID : P01 CA129243
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : U54 OD020355
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Oncologist. 2019 Aug;24(8):1095-1102
pubmed: 30975923
Cancer Discov. 2014 Apr;4(4):415-22
pubmed: 24469108
Cancer Cell. 2010 Mar 16;17(3):298-310
pubmed: 20227043
Clin Cancer Res. 2019 Aug 15;25(16):4966-4972
pubmed: 30988082
Oncogene. 1997 Sep 18;15(12):1385-94
pubmed: 9333014
Blood. 2005 Sep 1;106(5):1565-73
pubmed: 15920010
Cancer Res. 2010 Mar 15;70(6):2485-94
pubmed: 20215504
Sci Signal. 2009 Jun 30;2(77):ra31
pubmed: 19567914
J Natl Cancer Inst. 1973 Nov;51(5):1409-16
pubmed: 4357757
Clin Cancer Res. 2017 Jun 15;23(12):2981-2990
pubmed: 28011461
Cancer Discov. 2018 Jun;8(6):686-695
pubmed: 29610121
Oncotarget. 2016 Oct 25;7(43):69450-69465
pubmed: 27626312
NPJ Syst Biol Appl. 2017 Jan 05;3:16034
pubmed: 28725482
Cancer Cell. 2018 May 14;33(5):922-936.e10
pubmed: 29763625
Oncologist. 2021 Jan;26(1):7-16
pubmed: 32852072
J Pharmacokinet Biopharm. 1998 Feb;26(1):87-102
pubmed: 9773394
J Biomol Screen. 2009 Dec;14(10):1176-84
pubmed: 19887599
Clin Cancer Res. 2020 Jun 15;26(12):2932-2945
pubmed: 32122926
J Thorac Oncol. 2019 May;14(5):802-815
pubmed: 30831205
Oncotarget. 2018 Jan 03;9(11):9661-9671
pubmed: 29515761
Gynecol Oncol. 2015 Aug;138(2):372-7
pubmed: 26050922
J Immunol Methods. 2001 Jun 1;252(1-2):131-8
pubmed: 11334972
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Clin Cancer Res. 2015 May 1;21(9):1989-94
pubmed: 25501131
Oncogene. 1999 Oct 7;18(41):5718-21
pubmed: 10523851
Nat Med. 2017 Apr 7;23(4):405-408
pubmed: 28388612
Cancer Res. 2006 Feb 15;66(4):2116-28
pubmed: 16489012
Int J Gynecol Pathol. 2016 Sep;35(5):430-41
pubmed: 26974996
Clin Cancer Res. 2015 Apr 1;21(7):1752-63
pubmed: 25762344
Cell Cycle. 2020 Jan;19(2):163-178
pubmed: 31885322
Clin Cancer Res. 2014 Mar 15;20(6):1410-6
pubmed: 24520092
Cancer Med. 2016 Dec;5(12):3579-3585
pubmed: 27770508